UK-based charity commission Brain Tumour Charity has announced that the STELLAR trial, which will test the safety and efficacy of eflornithine, is now open for patients to enrol.

Eflornithine is an oral regimen used to treat patients identified with recurring anaplastic astrocytoma.

The STELLAR trial is a Phase III clinical trial that aims to study oral eflornithine as a possible novel treatment for recurrent anaplastic astrocytoma.

Funded by Orbus Therapeutices, the trial is now open to eligible patients for enrolment across North America, Europe and selected sites in the UK.

The Brain Tumour Charity commission said in a statement: “Anaplastic astrocytoma brain tumours are most common in adults aged 30 to 50 years, although it can affect all ages if they recur after surgery, chemotherapy or radiotherapy there are currently few treatments available, something the STELLAR trial aims to investigate.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This Phase III clinical trial is designed to show if eflornithine can inhibit malignant tumour growth, including intracerebral high-grade gliomas.

Under this trial, eflornithine will be administered orally and will target a key enzyme called ornithine decarboxylase. This enzyme plays a major role in the growth of cancer cells in the brain.

In 2014, eflornithine received breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of patients with anaplastic glioma.